Amazon partners with an old text stalwart. That is blackberry. How they plan to revolutionize tech. Those stories in a moment. The u. S. Stocks posting another record high amid news of new stimulus talks. They are progressing with a plan to pass by the weekend. Abigail doolittle has more on that. Also, i know you have been following the latest Earnings Results out of snowflake. Shares down after hours a bit. This is a big test for them after their blockbuster debut. Abigail it is. Lots of big movers relative to earnings after hours come snowflake being one of them. With snowflake, what you are referencing is that huge ipo, biggest ipo of the year back in september. This is their First Quarter as a publicly traded company, so they are finding out what it is about to these shares are absolutely plunging in the after hours, down 19 . This is an Application Software company, up just 37 year to date. They have struggled a little bit, and in this quarter they posted a wider loss than expecte
The missing billions the bank of england is urged to investigate where 50 billion pounds in banknotes is being kept. Thunder rumbles. Also coming up this hour. The phenomenon of this is bbc news. Thundersnow hits scotland. Residents in edinburgh are woken the headlines. In the middle of the night with time fast running out before by thunder and lightning combining with a heavy snowstorm. Current trade rules end on the 31st of december talks continue on a post brexit trade deal. An important day. Determination. We are in a difficult phase. There is no denying that. There are a number of tricky issues that have to be resolved. Americas top Infectious Disease expert apologises for suggesting that the uks s medical regulator had cut corners in giving speedy approval of the Coronavirus Vaccine. From this evening, pubs, bars and restaurants in wales will have to shut by six oclock and wont be allowed to sell alcohol other than ta ke aways. The uk will aim to cut its carbon good morning and w
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low.
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating.